Ibere Pharmaceuticals (IBER) Research

Ibere Pharmaceuticals currently lacks significant operational activities, with its core mission focused on executing a business combination. This could involve a merger, an acquisition of assets or shares, or a corporate restructuring with one or more other entities. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.

Market snapshot

Symbol
IBER
Price
$10.18
Day change
-0.29%
Market cap
$175.6M
P/E ratio
74.91x
52-week range
9.75-10.75
Sector
Financial Services
Industry
Shell Companies

Peer companies

  • AP Acquisition Corp. (APCA)
  • Bridgetown Holdings Limited (BTWN)
  • Fusion Acquisition Corp. II (FSNB)
  • Learn CW Investment Corporation (LCW)
  • Enphys Acquisition Corp. (NFYS)
  • Parabellum Acquisition Corp. (PRBM)
  • Slam Corp. (SLAM)
  • Tristar Acquisition I Corp. (TRIS)

Recent insider activity

  • Vollmer Louis J. — P-Purchase (10000 shares) on 2021-03-02
  • Kerekes Zoltan — trade (3350000 shares) on 2021-02-25
  • PIPV Capital LLC — trade (3350000 shares) on 2021-02-25
  • IMASOGIE OSAGIE O — trade (3350000 shares) on 2021-02-25
  • Vollmer Louis J. — trade (25000 shares) on 2021-02-25

Open Ibere Pharmaceuticals (IBER) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.